With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
